Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 OC6.2 | DOI: 10.1530/endoabs.39.OC6.2

BSPED2015 ORAL COMMUNICATIONS Oral Communications 6 (10 abstracts)

Mutations in BRAF are associated with septo-optic dysplasia and cardiofaciocutaneous syndrome

Louise Gregory 1 , Rachel Besser 1 , Karen Temple 2 , Justin Davies 3 & Mehul Dattani 1


1UCL Institute of Child Health, London, UK; 2Faculty of Medicine, University of Southampton, Southampton, UK; 3Department of Paediatric Endocrinology, Southampton Children’s Hospital, Southampton, UK.


Background: Mutations in BRAF are a rare cause of cardiofaciocutaneous syndrome (CFC). Recently, BRAF mutations have been reported in papillary craniopharyngiomas, but have not been described in patients with other hypothalamo-pituitary abnormalities. We describe three patients with CFC and septo-optic dysplasia (SOD) associated with heterozygous BRAF mutations.

Cases: Patients presented in childhood with clinical features of genetically proven CFC, short stature (height <0.4th centile) and MRI features of SOD. In cases 1 and 2, GH deficiency was initially observed (see Table 1), with case 1 subsequently developing gonadotrophin deficiency and a low-normal T4 and TSH, requiring levothyroxine replacement. Case 2 developed TSH deficiency and case 3 partial ACTH deficiency.

In situ hybridisation performed on human embryonic brain and hypothalamo-pituitary sections showed strong BRAF mRNA transcript expression at Carnegie stages (CS) 19, 20, 23, and 8 post-conception weeks, in the hypothalamus/ventral diencephalon, Rathke’s pouch, trigeminal ganglia, retina, spinal cord, and ganglia.

Table 1
Case/gender (M/F)Case 1 (M)Case 2 (F)Case 3 (F)
BRAF mutationc.770 A>G (p.Q257R)c.1403T>C (p.F468S)c.721 A>C (p.T241P)
GH peak (μg/l) (age/year)5.9 (2.5 years)a5.1 (9.7 years)b11 (6.2 years)b
IGF1 (μg/l), NR61, 20–18069, 111–55174, 88–474
fT4 (pmol/l) (age/year)16.6 (3.4 years), 10.3 (3.8 years)9.4 (9.8 years)Normal
 NR7.3–21.110.8–19.0
TSH (mU/l) (age/year)0.7 (3.4 years), 0.58 (3.8 years)3.0 (9.8 years)
 NR0.34–0.560.4–4.6
LH and FSH (IU/l) (age/year)Stimulated: 4.1, 8.0 (14.1 years)Basal: 44.5, 53.5 (13 years)-
Testosterone 0.5 nmol/lOestradiol: <44 pmol/l
Tanner stage11
Cortisol peak (nmol/l)--433c
MRI featuresSmall anterior pituitaryReduction in white matterPending
Absent corpus callosumEnlarged lateral ventricles
Hypoplastic optic nervesHypoplastic corpus callosum
Hypoplastic optic nerves
Normal anterior and posterior pituitary and stalk
NR, normal range; a, clonidine; b, glucagon stimulation; c, modified Synacthen.

Conclusion: We report the first novel association of SOD and CFC secondary to BRAF mutations. Endocrine features include GH deficiency, with evolution of other pituitary abnormalities. Patients with CFC should be screened for pituitary defects as these may be associated with morbidity. BRAF therefore appears to be implicated in normal hypothalamo-pituitary function.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.